PDF
(Download)
|
- Cinnamon (Cinnamomum verum syn. C. zeylanicum)
- Type 2 Diabetes
|
Date:
04-15-2013 | HC# 111236-470
|
Re: Cinnamon Intake May Improve Glycemic Status Indicators in People with Diabetes
Vafa
M, Mohammadi F, Shidfar F, et al. Effects of cinnamon consumption on glycemic
status, lipid profile and body composition in type 2 diabetic patients. Int J Prev Med. 2012;3(8):531-536.
The
incidence of type 2 diabetes mellitus is increasing worldwide. Controlling the
disease involves lifestyle changes, weight management, physical activity, and
healthy nutrition. The use of medicinal herbs with antihyperglycemic activities
is increasing among patients with diabetes. Cinnamon (Cinnamomum verum syn. C. zeylanicum)
has been shown to be an insulin sensitizer in both in vitro and in vivo studies;
however, in clinical trials on the effect of cinnamon on glucose and plasma
lipid concentrations in patients with diabetes, the results have been mixed.
These authors conducted a randomized, double-blinded, placebo-controlled trial
to investigate the benefit of cinnamon use in patients with type 2 diabetes.
Forty-four
patients were selected among patients at the Endocrinology and Metabolism
Center at Tehran University of Medical Sciences in Iran. The patients had to
have non-insulin-dependent type 2 diabetes, with hemoglobin A1c (HbA1c)
levels between 6% and 8% and fasting blood glucose (FBG) levels of 126-160
mg/dL.
The
patients were randomly assigned to either the cinnamon (n=22) or placebo (n=22)
group. Baseline characteristics did not differ among the patients. The mean age
of those in the cinnamon group was 54.11 ± 10.37 years; in the placebo group,
55.67 ± 7.98 years. Cinnamon and wheat flour (placebo) were ground finely and
put into capsules (500 mg each) that looked, smelled, and tasted the same. No
further information on the cinnamon capsules is provided. Patients ingested 2
capsules at each meal for 8 weeks. The patients continued their medications, maintained
their normal diet, and continued their usual physical activity throughout the
study. They completed 3-day food records at baseline and at the study's end. Compliance
was assessed by monitoring the return on capsule bottles and counting remaining
capsules.
Of
the 44 patients who began the study, 7 were excluded during the study. The
remaining 37 patients completed the study: 19 in the cinnamon group and 18 in the
placebo group.
At
baseline and at the end of the trial, each participant's weight, height, body
composition, and blood pressure were measured. Fasting blood samples were
collected also at those times to measure HbA1c and FBG and to
perform a lipid profile and insulin analysis.
Baseline
characteristics did not differ between the 2 groups; neither did energy intake,
macronutrient and micronutrient composition of the diet, or physical activity
during the study. The authors report significant reductions in FBG (9.2%;
P=0.005), HbA1c (6.12%; P=0.008), and triglyceride (15.38%; P=0.038)
levels in the cinnamon group at the end of the study compared with baseline
values. No such effect was seen in the placebo group. The reductions seen in
the cinnamon group were not significant when compared with the placebo group.
No
significant differences were noted within the groups in the insulin analysis or
lipid profile (total cholesterol, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, and apolipoproteins A-I and B) at the end of the study
compared with baseline values.
In
both groups, the patients had significant reductions in body weight (1.19%;
P=0.017) and body mass index (1.54%; P=0.010) at the end of the study compared
with baseline. Fat body mass, however, was reduced significantly only in the
cinnamon group (1.36%; P=0.047). No adverse effects were reported.
Among
the study's limitations were its short duration and the 3 g daily dose of cinnamon.
The authors explain that financial factors prevented them from including another
group using a higher dose of cinnamon to compare the effects of the different
doses.
The
authors compare their results with those of earlier studies using cinnamon in patients
with type 2 diabetes. They note that a positive correlation between baseline
plasma glucose and a decrease in plasma glucose in 1 study1 and a
strong decrease of serum glucose in patients with poorly controlled diabetes2
suggest that patients with poor glycemic control may benefit more from cinnamon
intake.
They
conclude that in patients with type 2 diabetes, the intake of 3 g of cinnamon
daily may have a moderate effect on glycemic status indicators.
—Shari Henson
References
1Mang B, Wolters M,
Schmitt B, et al. Effects
of a cinnamon extract on plasma glucose, HbA1c, and serum lipids in
diabetes mellitus type 2. Eur J Clin
Invest. 2006;36(5):340-344.
2Khan A, Safdar M, Ali
Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of
people with type 2 diabetes. Diabetes
Care. 2003;26(12):3215-3218.
|